Intensive blood pressure control may slow age-related brain damage
NINDS: Christopher G. Thomas | 301-496-5751 | firstname.lastname@example.org
NIA: Joe Balintfy | 301-496-1752 | email@example.com
NHLBI: Hillary Viers | 301-496-5449 | firstname.lastname@example.org
NIDDK: January Payne | 301-496-3583 | email@example.com
NIH-funded imaging study shows link between blood pressure and white matter lesions
In a nationwide study, researchers used magnetic resonance imaging (MRI) to scan the brains of hundreds of participants in the National Institutes of Health’s Systolic Blood Pressure Intervention Trial (SPRINT) and found that intensively controlling a person’s blood pressure was more effective at slowing the accumulation of white matter lesions than standard treatment of high blood pressure. The results complement a previous study published by the same research group which showed that intensive treatment significantly lowered the chances that participants developed mild cognitive impairment.
“These initial results support a growing body of evidence suggesting that controlling blood pressure may not only reduce the risk of stroke and heart disease but also of age-related cognitive loss,” said Walter J. Koroshetz, M.D., director of the NIH’s National Institute of Neurological Disorders and Stroke (NINDS). “I strongly urge people to know your blood pressure and discuss with your doctors how to optimize control. It may be a key to your future brain health.”
Brain white matter is made up of billions of thin nerve fibers, called axons, that connect the neurons with each other. The fibers are covered by myelin, a white fatty coating that protects axons from injury and speeds the flow of electrical signals. White matter lesions, which appear bright white on MRI scans, represent an increase in water content and reflect a variety of changes deep inside the brain, including the thinning of myelin, increased glial cell reactions to injury, leaky brain blood vessels, or multiple strokes. These changes are associated with high blood pressure, or “hypertension.”
As described on the NIH’s Mind Your Risks website, several studies have suggested that people who have hypertension have a greater chance of accumulating white matter lesions and also of experiencing cognitive disorders and dementia later in life.
These observations were tested in a “gold standard” randomized clinical trial, called SPRINT Memory and Cognition in Decreased Hypertension (MIND), which examined whether controlling blood pressure levels could prevent or slow white matter lesion progression and aging brain disorders. The results were published on Aug. 13, 2019 in the Journal of the American Medical Association.
“These findings on white matter lesions—primarily in the aggressive control of blood pressure—are encouraging as we continue to advance the science of understanding and addressing the complexities of brain diseases such as Alzheimer’s and related dementias,” said Richard J. Hodes, M.D., director of the NIH’s National Institute on Aging (NIA).
Launched in 2010, the NIH-supported SPRINT effort initially enabled scientists to compare the effects of standard versus intensive blood pressure control on cardiovascular health and mortality. More than 9,300 adults who were at least 50 years old and had a high risk for cardiovascular disease received either standard treatment, which lowered systolic blood pressure, the first of two numbers measured during an exam, to less than 140 mm Hg (<140 mm Hg), or intensive treatment to lower the same pressure reading below 120 mm Hg (<120 mm Hg). In August 2015, NIH surprisingly ended the trial early after initial results showed that 3.3 years of intensive treatment significantly reduced the rates of death and cardiovascular disease.
The NIA and NINDS supported sub-study, SPRINT MIND, enabled scientists from 27 clinical sites to examine the effects these treatments had on the brain by measuring cognitive function and acquiring MRI scans on a subset of SPRINT participants. The researchers compared brain scans of 449 participants that were taken at enrollment and four years later. During this time, the average increase in total volume of white matter lesions on scans of the intensive treatment group was 0.92 cm3, which was less than the 1.45 cm3 seen on scans from the standard treatment participants.
“Intensive treatment significantly reduced white matter lesion accumulation in people who had a higher chance of experiencing this kind of damage because they had high blood pressure,” said Clinton B. Wright, M.S., M.D., director of the Division of Clinical Research at NINDS, and an author of the study.
The SPRINT MIND researchers also reported slightly more loss of brain volume in the intensive treated group than those in the standard treatment. The effect was seen predominantly in males. However, the authors noted this loss was generally very small and of unclear clinical significance.
“SPRINT MIND has produced promising initial results in the battle against the nation’s growing problem with aging brain disorders. Both the brain scans and the cognitive tests reinforce the potential benefits that intensive blood pressure management may have on the brain,” said Lenore J. Launer, Ph.D., a senior investigator in the NIA Laboratory of Epidemiology and Population Sciences and co-author of the paper. “We hope that these findings will become the foundation for future studies on how to protect the brain throughout a person’s life.”
In the future, SPRINT MIND researchers plan to look at how controlling blood pressure may affect the accumulation of white matter lesions in critical regions of the brain affected by aging brain disorders and what factors may make some people more responsive to treatment.
The SPRINT MIND Investigators for the SPRINT Research Group. Association of intensive versus standard blood pressure control with cerebral white matter lesions. JAMA, August 13, 2019 DOI: 10.1001/jama.2019.10551
These studies were supported by the NIH’s Systolic Blood Pressure Intervention Trial, which was jointly funded by the National Heart, Lung, and Blood Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Aging, and the National Institute of Neurological Disorders and Stroke (HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, and HHSN268200900049C and interagency agreement A-HL-13-002-001), and the following NIH grants: OD023495, TR000439, RR025755, RR024134, TR000003, RR025771, TR000093, RR025752, TR000073, TR001064, TR000050, TR000005, TR000017, TR000105, TR000445, TR000075, TR000002, TR000064, TR000433, GM103337. Additional funding was provided by the Department of Veterans Affairs. Azilsartan and chlorthalidone (combined with azilsartan) were provided by Takeda Pharmaceuticals International Inc.
Clinical Trial Number: NCT01206062
For more information:
NIA Health Information on Dementia
NIH Mind Your Risks Website®
National Institute on Aging
National Heart, Lung, and Blood Institute
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Neurological Disorders and Stroke
About the National Heart, Lung and Blood Institute (NHLBI): The NHLBI plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders. The Institute also administers national health education campaigns on women and heart disease, healthy weight for children, and other topics. NHLBI press releases and other materials are available online at the NHLBI website.
About the National Institute on Aging (NIA): NIA leads the U.S. federal government effort to conduct and support research on aging and the health and well-being of older people. Learn more about age-related cognitive change and neurodegenerative diseases via NIA’s Alzheimer's Disease Education and Referral (ADEAR) Center website. For information about a broad range of aging topics, visit the main NIA website and stay connected.
About the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): The NIDDK, part of the NIH, conducts and supports basic and clinical research and research training on some of the most common, severe, and disabling conditions affecting Americans. The Institute’s research interests include diabetes and other endocrine and metabolic diseases; digestive diseases, nutrition, and obesity; and kidney, urologic, and hematologic diseases. For more information, visit the NIDDK website.
About the National Institute of Neurological Disorders and Stroke (NINDS): NINDS is the nation’s leading funder of research on the brain and nervous system. The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit the NIH website.
NIH...Turning Discovery Into Health®